Hanmi Science Co Ltd

Hanmi Science maintains a relatively strong liquidity position with KRW 127.39 billion in cash and equivalents, but its current ratio of 0.88 indicates that current liabilities exceed current assets, suggesting potential short-term liquidity constraints. The company's debt-to-equity ratio of 0.22 reflects a conservative capital structure, with long-term debt of KRW 214.53 billion compared to total equity of KRW 961.85 billion. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling a need for careful monitoring of liquidity pressures. Profitability metrics show a return on equity (ROE) of 12.31% and a return on assets (ROA) of 7.95%, both of which are strong indicators of efficient capital use and asset management. The company's operating income of KRW 138.73 billion and net income of KRW 118.37 billion reflect solid earnings performance, although these figures should be compared to industry medians to assess relative competitiveness. Geographically, Hanmi Science's revenue is concentrated in South Korea, with no disclosed international segments in the latest financial data. The company's business is primarily driven by its domestic pharmaceutical operations, which exposes it to regulatory and market risks specific to the Korean healthcare sector. Looking ahead, Hanmi Science is expected to maintain a stable growth trajectory, with revenue and earnings likely to remain consistent in the near term. The company's free cash flow of KRW 92.27 billion and capital expenditure of KRW -20.91 billion suggest a disciplined approach to reinvestment and capital preservation. However, the absence of disclosed R&D or capex outlooks limits visibility into long-term growth drivers. The risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure from share issuance or dilution events. The company's ESG score of 26.18 and a C- grade indicate room for improvement in environmental, social, and governance practices. The ESG controversies score of 100 suggests the company has not been involved in major controversies, which is a positive signal. Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly alter the company's financial or operational trajectory. The company's focus remains on its core pharmaceutical business, with no disclosed expansion into new therapeutic areas or geographic markets.